The Twelve-Week Review Clock and What Actually Starts It

1. Key takeaways

The two official time intervals are these: an acknowledgement email is issued about 2 weeks after an application is submitted, together with an application number carrying a prefix such as AN, IAN, DAN or LMAN; and the approval process is generally completed within 12 weeks after submission and all required supporting information. The critical point is that the 12 weeks run from the moment the file is complete, not from the moment it is submitted. The clock pauses while supplementary information is being supplied, and an incomplete response may result in the application being returned. Working backwards on that basis, the conservative budget from a standing start to a certificate is 14 weeks or more (practical estimate).

• The acknowledgement step is a distinct checkpoint: a submission that has not been acknowledged has not necessarily been received into the system.
• The application number is the key that links every later action, including supplementation, enquiries and expedited scheme eligibility.
• Supplementary information requests are the largest single variable in the timeline, because they suspend the review rather than run alongside it.
• A returned application restarts the queue, which means the 12 weeks begin again rather than resuming from the point of return.
• The 2-week response obligation under the expedited scheme is a second, separate clock that has to be managed in parallel.

2. Legal basis

The time intervals are stated in the Medical Device Administrative Control System (MDACS) information page and repeated in the Medical Device Division (MDD) overview of the listing process, while the consequences of an incomplete response sit in the guidance that governs application handling. The table below lists the sources and the provisions relied on in this article.

The repetition of the same intervals across an information page, a procurement document and a guidance matters for planning. It means the 12-week figure is not a service target published in one place and quietly exceeded elsewhere; it is the figure that procurement documents themselves rely on, and therefore the figure against which commercial commitments will be measured by customers and tender authorities.

3. Expert insights

First, the 2-week acknowledgement is an underestimated risk line. MDD states explicitly that an applicant who has not received an acknowledgement email within 2 weeks of submission should contact MDD to check whether the application has been received. That instruction acknowledges a blind spot between submission and acceptance: an electronic filing is not the same thing as an accepted application, and a project that assumes otherwise can lose weeks before anyone notices that nothing is moving.

Second, the application number indexes everything that follows. Numbers are distinguished by prefix, with AN for device listing, IAN for importers, DAN for distributors and LMAN for local manufacturers. Once a number is allocated, later supplementation, enquiries and expedited scheme eligibility are all tied to it. Recording the number promptly, and quoting it in every communication, is a small discipline that prevents correspondence from being matched to the wrong file.

Third, supplementation is the biggest variable in the time account. The official overview makes clear that MDD may request supplementary information during assessment and that, where the information remains insufficient within the specified period, the application will be returned. A return means joining the queue again and the 12 weeks starting over. The practical implication is that the quality of the first submission, rather than the speed of the response to the first request, determines the delivery date.

Fourth, the 2-week response under the expedited scheme is an additional constraint. Applicants taking part in the expedited approval scheme must respond within 2 weeks of an MDD notification, failing which the application may be converted back to an ordinary application. This runs on a different track from the ordinary supplementation period, so the two timelines have to be managed separately rather than assumed to be the same obligation described twice.

4. Practical recommendations

• Set a reminder at submission. On the 10th working day after filing, check whether the acknowledgement email has arrived; if it has not, telephone MDD on 3107 8484 to confirm receipt.
• Complete the file in one pass. Treat the completeness of the first submission as a project KPI, because the number of supplementation rounds drives the actual calendar time more than any other factor.
• Build a countback schedule. Start from the target effective date, such as a tender deadline or 1 March 2027, count back 14 weeks to fix the submission date, and count back again to schedule appointment of the Local Responsible Person (LRP) and dossier preparation.
• Assign an owner to supplementation. Record each request in a separate log with the specified deadline and the responsible person, and escalate the risk of late response to management.

5. Verification checklist

• □ Submission date recorded and a 2-week acknowledgement checkpoint set
• □ Application number obtained and filed (AN, IAN, DAN or LMAN)
• □ Completeness of the first submission has passed internal review
• □ A supplementation log exists with a named responsible person
• □ Submission date counted back from the target effective date with at least 14 weeks allowed
• □ Where the expedited scheme is used, a 2-week response mechanism is in place

Regulatory information verified to 29 October 2026. The legislation, guidance and effective dates described in this article are limited to what the official sources listed under Legal basis had published on that date; where an official document has since been updated, the most recent published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team manages MDACS listing applications across all risk classes, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com